Skip to main content
. 2020 Aug 21;10:1216. doi: 10.3389/fonc.2020.01216

Figure 2.

Figure 2

Progression-free survival (PFS) according to baseline next-generation sequencing (NGS) data. (A) Patients were categorized into three subgroups: EML4-ALK rearrangements (n = 121), non-EML4-ALK rearrangements (n = 5), and EML4-ALK rearrangements accompanied by non-EML4-ALK rearrangements (n = 6). (B) Patients with different EML4-ALK variants: variant 1 (n = 49), variant 3a/b (n = 40), and other variants (n = 43). (C) Patients with oncogene mutations (n = 16) vs. patients without oncogene mutations (n = 116). (D) Patients with tumor-suppressor gene mutations (n = 43) vs. patients without tumor-suppressor gene mutations (n = 89). HR, hazard ratios; CI, confidence interval; p-values were calculated using the log-rank test.